CN102441008B - Containing the hair growth agent of blood platelet dry powder - Google Patents
Containing the hair growth agent of blood platelet dry powder Download PDFInfo
- Publication number
- CN102441008B CN102441008B CN201010512614.XA CN201010512614A CN102441008B CN 102441008 B CN102441008 B CN 102441008B CN 201010512614 A CN201010512614 A CN 201010512614A CN 102441008 B CN102441008 B CN 102441008B
- Authority
- CN
- China
- Prior art keywords
- dry powder
- hair growth
- blood platelet
- hair
- growth agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001772 blood platelet Anatomy 0.000 title claims abstract description 74
- 230000003779 hair growth Effects 0.000 title claims abstract description 63
- 239000000843 powder Substances 0.000 title claims abstract description 55
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 210000004209 hair Anatomy 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 35
- 238000005507 spraying Methods 0.000 claims description 9
- 230000035515 penetration Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 2
- 206010020880 Hypertrophy Diseases 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000037308 hair color Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000003324 growth hormone secretagogue Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 238000009700 powder processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention is relevant a kind of hair growth agent and using method thereof, and espespecially one utilizes blood platelet dry powder constituent as trichogenous hair growth agent and using method thereof.A kind of hair growth agent, its blood platelet dry powder containing effective dose and medical acceptable solvent and/or excipient, wherein so-called effective dose, refer in every milligram of hair growth agent, at least containing 1,000 platelet cell.
Description
Technical field
The present invention is relevant a kind of hair growth agent and using method thereof, and espespecially one utilizes blood platelet dry powder constituent as trichogenous hair growth agent and using method thereof.
Background technology
Depilation phenomenon is the dream dimple of many people, therefore, how to promote that hair growth becomes a kind of important technology, such as TaiWan, China the 200841886th publication case discloses: containing the active component of 0.02% ~ 2.0% nitrite, and contains two agent hair growth agents of 0.5 ~ 4% sour agent active component, TaiWan, China the 200413014th publication case discloses: containing the hair growth agent of the growth/transcription factor of performance exception, other is TaiWan, China the 128728th, 191212,260665,474821,490307,501931,592719 issued patents case such as, and TaiWan, China the 200509957th, 200612904,200825399 publication case etc. discloses respectively and utilizes small-molecule chemical medicine as the hair growth agent chemical formulation of active component, Taiwan the 518220th issued patents case discloses and utilizes fkbp ligand body as the hair growth agent prescription of active component, TaiWan, China the 531419th issued patents case discloses and utilizes serine protease as the hair growth agent prescription of active component, TaiWan, China the 200409650th publication case discloses the hair growth agent prescription utilizing vitamin and/or coenzyme as active component, TaiWan, China the 200509972nd, 200529876 and 200942251 publication cases disclose and utilize plant extract as the hair growth agent prescription of active component, TaiWan, China the 200815038th publication case discloses and utilizes estrogen source as the hair growth agent prescription of active component, but without any the hair growth agent utilizing blood platelet dry powder as active component.With United States Patent (USP), utilize platelet related substances as the hair growth agent patent of active component, also only have the U.S. the 20050049268th publication application case, this Patent Case discloses: with the hair growth agent of pdgf receptor tyrosine kinase inhibitor (PDGF receptor tyrosine kinases inhibitor) as active component.First the present invention discloses: with the hair growth agent of blood platelet dry powder as active component, and be actually used in the hair growth of human body, obtains very successfully result.
Summary of the invention
An object of the present invention is to provide a kind of blood platelet dry powder as trichogenous novelty teabag.
Two of object of the present invention is to provide a kind of with the hair growth agent of blood platelet dry powder as active component.
Three of object of the present invention is to provide a kind of with the trichogenous method of blood platelet dry powder formula.
Hair growth agent of the present invention, is applicable to the growth promoting animal hair, the especially hair of people, such as hair, eyebrow.
Hair growth agent of the present invention, it, containing blood platelet dry powder of hair growth effective dose and medical acceptable solvent and/or excipient, wherein so-called effective dose, refers in every milligram of hair growth agent, at least containing 1,000 platelet cell.1,000 to 15,000 platelet cell is contained in every milligram of hair growth agent in a preferred embodiment of the present invention.
Above-mentioned blood platelet dry powder, for utilizing blood or Blood Preparations, such as thrombocyte plasma (platelet-rich
Plasma, hereinafter referred to as PRP), via ad hoc approach, make the blood platelet dry powder containing complete platelet cell.Making the technology of blood platelet dry powder, is blood platelet dry powder manufacturing technology known arbitrarily, for example, see TaiWan, China I300806, I270375 issued patents case, TaiWan, China the 201004659th, 200526680 publication case, the U.S. 7,659,052,7,202,020,7,169,606,6,060,233,5,736,313,5,589,462 issued patents cases, certain blood platelet dry powder of the present invention is not limited to above-mentionedly quote person made by method described in case as proof.Above-mentioned blood platelet dry powder, different with processing procedure, will containing a small amount of anticoagulant, protective agent etc., the processing procedure such as disclosed with TW-I270375 issued patents case manufactures blood platelet dry powder, will containing a small amount of resisting blood coagulation citrate dextrose liquid (Acid Citrate Dextrose), freezing precipitation agent (cryoprecipitate; Cryo, fibrinogen) and thrombin (thrombin), but these compositions can not affect in fact the usefulness of blood platelet dry powder, therefore need not deliberately remove.
Above-mentioned hair growth agent can be dosage form known arbitrarily, such as solution, suspension, unguentum, powder, pill etc., and being better with solution, ointment or percutaneous absorbtion medicament, is better with spray or ointment.As for powder, pill etc., in time using, other applicable dosage form can be modulated into.
The acceptable solvent of above-mentioned medicine, refer to and can take orally as the mankind or animal arbitrarily or the solvent of external, such as alcohol-water cosolvent, water, normal saline solution etc., be better with water or normal saline solution.The amount that solvent adds, can maintain the platelet cell of effective dose for principle.
The acceptable excipient of medicine, needs to adopt known excipient according to dosage form.
The effective dose of above-mentioned blood platelet dry powder is in every milligram of hair growth agent, and at least containing 1,000 platelet cell, being better at least to contain 2,000 platelet cell, is better at least to contain 5,000 platelet cell.
Above-mentioned hair growth agent additionally can have arbitrarily the effective ingredient (such as anti-inflammation components, analgesic component, nutritional labeling and/or can promote the composition of absorption) of positive effect, or does not have in fact the composition (such as spice) of counter productive or side effect.
Above-mentioned blood platelet dry powder can be (heterologous) of allos, (homologous) of homology or autologous (autologous) blood platelet dry powder, psychology based on user is considered, this blood platelet dry powder is better with the blood platelet dry powder of homology or autologous blood platelet dry powder, is better with autologous blood platelet dry powder.
Generally speaking, hematoblastic PDGF (platelet-derivatives growth factor) is about 40 ~ 200pg/mL, see Vogt., et al., Determination of endogenous growth factors in humanwound healing.Wound Repair Regeneration, 2004,12 (4): p.485-492., the effectiveness of hair growth agent of the present invention may be relevant with the PDGF long-effect active of blood platelet dry powder, but its certain dependency still treats further confirmation.
Trichogenous method of the present invention, it comprises:
One cleanup step, in order to make to treat that trichogenous position becomes to be suitable for the state processed; And
One spraying process, it is by the hair growth agent of blood platelet dry powder containing effective dose, spraying or coat this position through cleaning, and wherein so-called effective dose, refers in every milligram of hair growth agent, at least containing 1,000 platelet cell.
Above-mentioned so-called cleanup step refers to such as washs, sterilizes, maybe will treat that trichogenous position is carded to the state etc. being suitable for processing.Generally speaking, whether wash the clean conditions depending on this pending position during process, with wash in advance or on-the-spot washing for better; The not required that they be so though whether sterilize, really to sterilize as better; Whether combing hair depends on the needs, if pending position does not have in fact or does not almost have hair, certainly can without combing (if but its surrounding still has hair time, surrounding hair should be combed from pending position), if there is hair at pending position in fact, hair should be carded to the state being suitable for processing.
Above-mentioned spraying process, by the hair growth agent of the blood platelet dry powder containing effective dose, according to its dosage form spraying or coat described through cleaning position, such as, when described hair growth agent is solution, using spray mode makes hair growth agent evenly spray in treating trichogenous position; When described hair growth agent is ointment, available coating method makes hair growth agent be spread evenly across and treats trichogenous position.
The relevant information of above-mentioned hair growth agent is as aforementioned.
Above-mentioned trichogenous method, be applicable to the crinite animal of tool, the especially mankind, are also applicable to house pet certainly.
For making trichogenous better effects if, can increase by a penetration enhancement step, this penetration enhancement step can before cleanup step, among or afterwards; Generally speaking, being better before combing after sterilisation.
This penetration enhancement step can be the mode being conducive to arbitrarily penetration enhancement hair growth agent, such as massage or laser massage are to promote the blood circulation, electromagnetic wave importing, micropin perforation etc. of hair follicle, boring a hole as better with electromagnetic wave importing or micropin, is better with micropin perforation.
Accompanying drawing explanation
Photo 1a is the photo of hair before the patient treatment of embodiment 1, and photo 1b, 1c, 1d are the hair photo after this patient treatment.
Photo 2a is the photo of hair before the patient treatment of embodiment 2, and photo 2b, 2c are the hair photo after this patient treatment.
Photo 3a is the photo of hair before the patient treatment of embodiment 3, and photo 3b, 3c are the hair photo after this patient treatment.
Photo 4a is the photo of hair before the patient treatment of embodiment 4, and photo 4b, 4c are the hair photo after this patient treatment.
Photo 5a is the photo of hair before the patient treatment of embodiment 5, and photo 5b is the hair photo after this patient treatment.
Photo 6a is the photo of hair before the patient treatment of embodiment 6, and photo 6b is the hair photo after this patient treatment.
Photo 7a is the photo of hair before the patient treatment of embodiment 7, and photo 7b is the hair photo after this patient treatment.
Photo 8a is the photo of hair before the patient treatment of embodiment 8, and photo 8b is the hair photo after this patient treatment.
Photo 9a is the photo of hair before the patient treatment of embodiment 9, and photo 9b is the hair photo after this patient treatment.
Detailed description of the invention
For further illustrating the technology of the present invention, be hereby described as follows with preferred embodiment:
Test case:
With the processing procedure that TW-I270375 issued patents case discloses, manufacture blood platelet dry powder.Get 1.0 grams of blood platelet dry powders, add normal saline solution and be mixed with 5.0 milliliters, then respectively when preparation completes (0 week), after one week, after two weeks, three weeks afterwards, after surrounding, after five weeks, after six weeks, with sub-ray spectrometer (U.S. Bio-TekInstruments, Inc., model μ-Quant) to analyze PDGF and tire, result is as table 1.
Table 1: in the solution that blood platelet dry powder configures, the change of tiring of PDGF.
Experimental data shows: the PDGF in this blood platelet dry powder tires highly stable.
Embodiment 1.
The processing procedure disclosed with TW-I270375 issued patents case in advance, manufactures autologous blood platelet dry powder to autologous blood.Add reverse osmosis water with this blood platelet dry powder, make 1, the solution of 000 platelet cell, and be contained in spray bottle.
Weekly trichogenous treatment procedure is carried out once to patient, that is treat promote hair growth position carry out disinfection, then with micropin roller (micro-roller, purchased from Korea S Daesung Medical Co.Ltd., model Mi-Roll-1), roll (micropin perforation) at the position of sterilizing, then spray the position in this sterilization uniformly with hair growth agent (solution).Between two treatments program, after hair washing every day, simple evenly spraying with this hair growth liquor waits to promote hair growth position.
Before its treatment, treat 3 weeks after wait promote that the hair at hair growth position is respectively as shown in photo 1a, 1b, though there is the phenomenon of hair hypertrophy, not obvious.
Roughly the same above-mentioned therapeutic modality, but raising growth stimulator concentration is 2,000 platelet cell number/milliliter, and the phenomenon of the hair hypertrophy of 4th week obviously compares first three week obviously, see photo 1c.
Roughly the same above-mentioned therapeutic modality, but raising growth stimulator concentration is 5,000 platelet cell number/milliliter, and by the 8th week, the relative 4th week of phenomenon of hair hypertrophy was more obvious, and a new hypertrophy is a lot, see photo 1d.
Embodiment 2.
Roughly the same embodiment 1, but blood platelet dry powder for take from blood bank blood made by the blood platelet dry powder of homology, growth stimulator concentration (platelet cell number/ml soln) 5,000.Before treatment, the treatment hair at promotion hair growth position of 5 weeks, 7 weeks respectively as shown in photo 2a, 2b, 2c, be respectively the enlarged drawing of this photo Blocked portion on the right side of each photo.Result shows: new (hair color) significantly hypertrophy, a strain of old is thicker.
Embodiment 3.
Roughly the same embodiment 2, before its treatment, the treatment hair at promotion hair growth position of 1 week, 3 weeks respectively as shown in photo 3a, 3b, 3c, be respectively the enlarged drawing of this photo Blocked portion on the right side of each photo.Result shows: new (hair color) significantly hypertrophy, a strain of old is thicker.
Embodiment 4.
Roughly the same embodiment 2, before its treatment, the treatment hair at promotion hair growth position of 5 weeks, 7 weeks respectively as shown in photo 4a, 4b, 4c, be respectively the enlarged drawing of this photo Blocked portion on the right side of each photo.Result shows: new (hair color) significantly hypertrophy, a strain of old is thicker.
Embodiment 5.
Roughly the same embodiment 2, before its treatment, treats the hair at promotion hair growth position of 4 weeks respectively as shown in photo 5a, 5b, is respectively the enlarged drawing of this photo Blocked portion on the right side of each photo.Result shows: new (hair color) significantly hypertrophy, a strain of old is thicker.
Embodiment 6.
Roughly the same embodiment 2, before its treatment, the hair at all promotion hair growth position for the treatment of 5 weeks respectively as shown in photo 6a, 6b, be respectively the enlarged drawing of this photo Blocked portion on the right side of each photo.Result shows: new (hair color) significantly hypertrophy, a strain of old is thicker.
Embodiment 7.
Roughly the same embodiment 2, before its treatment, treat the hair at promotion hair growth position of 2 weeks respectively as shown in photo 7a, 7b, result shows: newly send out remarkable hypertrophy, and a strain of old is thicker.
Embodiment 8.
Roughly the same embodiment 2, before its treatment, treats the hair at promotion hair growth position of 6 weeks respectively as shown in photo 8a, 8b, is respectively the enlarged drawing of this photo Blocked portion on the right side of each photo.Result shows: new (hair color) significantly hypertrophy, a strain of old is thicker.
Embodiment 9.
Roughly the same embodiment 2, before its treatment, treat the hair at promotion hair growth position of 6 weeks respectively as shown in photo 9a, 9b, result shows: newly send out remarkable hypertrophy, and a strain of old is thicker.
Embodiment 10 ~ 24.
Roughly the same embodiment 2 ~ 9, blood platelet dry powder processing procedure is identical.Hair growth promoter concentration (unit is platelet cell number/ml soln), 4 weeks curative effects and 8 weeks curative effects are see table 2.In table, the blood platelet dry powder of homology is that the blood platelet dry powder of allos makes with Sanguis Bovis seu Bubali, and the course for the treatment of, record was respectively 4,8 weeks made by the blood taking from blood bank.
Table 2: the treatment condition of embodiment 2 ~ 6 and therapeutic outcome
Table 2 result shows: single with curative effect, the blood platelet dry powder of allos seems slightly to be better than the blood platelet dry powder of homology and autologous blood platelet dry powder.But consideration patients ' psychological, to adopt the blood platelet dry powder of homology or autologous blood platelet dry powder for better, is better with autologous blood platelet dry powder.
Claims (10)
1. one kind uses blood platelet dry powder in the purposes manufacturing hair growth agent, wherein this hair growth agent contains the blood platelet dry powder of effective dose and medical acceptable solvent, wherein so-called effective dose, refer in every milliliter of hair growth agent, containing 2,000,5,000,10000 or 15,000 platelet cell.
2. purposes as claimed in claim 1, wherein said blood platelet dry powder is autologous blood platelet dry powder.
3. purposes as claimed in claim 1, wherein said solvent is water or normal saline solution.
4. a trichogenous method for non-treatment object, it comprises:
One spraying process, it is by the hair growth agent of blood platelet dry powder containing hair growth effective dose, spraying or coat the position of a hair growth, wherein so-called effective dose, refers in every milliliter of hair growth agent, containing 2,000,5,000,10000 or 15,000 platelet cell.
5. method as claimed in claim 4, it comprises a cleanup step in taking a step forward of spraying process, and it is washing, sterilizes or comb hair from treating trichogenous position.
6. method as claimed in claim 5, it is further containing a penetration enhancement step, this penetration enhancement step be before cleanup step, among or carry out afterwards.
7. method as claimed in claim 6, wherein said penetration enhancement step is carried out after the cleaning step.
8. method as claimed in claim 5, wherein said hair growth agent is the blood platelet dry powder solution containing effective dose, and this spraying process is sprayed by this blood platelet dry powder solution in this position through cleaning.
9. method as claimed in claim 8, the solvent that wherein said solution uses is water or normal saline solution.
10. method as claimed in claim 5, wherein said blood platelet dry powder is autologous blood platelet dry powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010512614.XA CN102441008B (en) | 2010-10-09 | 2010-10-09 | Containing the hair growth agent of blood platelet dry powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010512614.XA CN102441008B (en) | 2010-10-09 | 2010-10-09 | Containing the hair growth agent of blood platelet dry powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102441008A CN102441008A (en) | 2012-05-09 |
| CN102441008B true CN102441008B (en) | 2015-09-09 |
Family
ID=46004268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010512614.XA Active CN102441008B (en) | 2010-10-09 | 2010-10-09 | Containing the hair growth agent of blood platelet dry powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102441008B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201544126A (en) * | 2014-05-21 | 2015-12-01 | Ming-Hsuan Sung | Purpose of platelet derived growth factor using for turning white hair black |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049268A1 (en) * | 2001-11-21 | 2005-03-03 | Francois-Xavier Mahon | Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation |
| TW201004659A (en) * | 2008-07-18 | 2010-02-01 | Hemogen Bio Tech Co Ltd | Method to preserve autologous platelets dry powder |
| KR20100097574A (en) * | 2009-02-26 | 2010-09-03 | 김민 | Cell composition for promoting hair growth |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05124935A (en) * | 1991-10-31 | 1993-05-21 | Kao Corp | Hair growth promoter |
-
2010
- 2010-10-09 CN CN201010512614.XA patent/CN102441008B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049268A1 (en) * | 2001-11-21 | 2005-03-03 | Francois-Xavier Mahon | Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation |
| TW201004659A (en) * | 2008-07-18 | 2010-02-01 | Hemogen Bio Tech Co Ltd | Method to preserve autologous platelets dry powder |
| KR20100097574A (en) * | 2009-02-26 | 2010-09-03 | 김민 | Cell composition for promoting hair growth |
Non-Patent Citations (1)
| Title |
|---|
| Involvement of Platelet-Derived Growth Factor Receptor-α in Hair Canal Formation;Nobuyuki Takakura, etc.;《Journal of Investigative Dermatology 》;19961130;第107卷(第5期);第770-777页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102441008A (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ozog et al. | Photodynamic therapy: a clinical consensus guide | |
| CN106794337A (en) | Portable medical treatment system and application method | |
| TWI422385B (en) | Hair growth agent containing platelet dry powder | |
| CN102441008B (en) | Containing the hair growth agent of blood platelet dry powder | |
| CN103230359A (en) | Anti acne mask with anti acne efficacy and preparation method thereof | |
| CN102462652B (en) | Containing the skin promoter of blood platelet dry powder | |
| CA2884306C (en) | A method for the permanent removal of hair | |
| KR20090049390A (en) | The manufacturing method of natural unfalling out of hair | |
| CN105477195A (en) | Medicine for treating skin injury and preparation method of medicine | |
| CN101849992A (en) | Medicament for treating inferior turbinate hypertrophy and method for preparing same | |
| US20170196799A1 (en) | Skincare stimulant having a platelet dry powder | |
| US20170128356A1 (en) | Skincare stimulant having a platelet dry powder | |
| US20160000700A1 (en) | Method for promoting hair growth | |
| Katsambas et al. | Disorders of pigmentation: unapproved treatments | |
| US20160354407A1 (en) | Formulations of Antimicrobial, Antiviral, and Antineoplastic Compounds In Combination With Certain Wavelengths of Light | |
| D'Erme et al. | Emerging treatments for vitiligo | |
| KR20040037049A (en) | The manufacturing method of natural unfalling out of hair | |
| Sethi | Efficacy of platelet rich plasma for treatment of Male Androgenetic Alopecia patients: A Prospective Clinical Study | |
| TWM651448U (en) | Hair care and strengthening equipment | |
| CN105267951B (en) | A kind of nanometer silver antimicrobial ionized water wound care composition | |
| CN113116984A (en) | Herbal formula for treating beriberi | |
| WO2019135199A1 (en) | Compositions and methods for exogenous pigment removal | |
| protection as well as SunCat | Bio-Pharmaceuticals Sdn Bhd (514236-M) | |
| Rybak et al. | LavTIME–A Brand-New Treatment Method of Lasting Wounds–A Multi-Centre Randomized Double-Blind Study on Effectiveness of Polyhexanide and Betaine in Ulcers’ Healing with Venous Origin | |
| Bakhtar | Amazing Topical Protocol and Novel Powder Dressing Combination Formula in Treatment of Diabetic Foot Wounds. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120509 Assignee: Thinking biotech Limited by Share Ltd. Assignor: Central Medical Technologies Inc. Contract record no.: 2017990000199 Denomination of invention: Hair growth stimulator containing platelet powder Granted publication date: 20150909 License type: Exclusive License Record date: 20170524 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Thinking biotech Limited by Share Ltd. Assignor: CENTRAL MEDICAL TECHNOLOGIES Inc. Contract record no.: 2017990000199 Date of cancellation: 20210526 |
|
| EC01 | Cancellation of recordation of patent licensing contract | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210701 Address after: 6th floor, 298 Ruiguang Road, Neihu district, Taipei, China Patentee after: Thinking biotech Limited by Share Ltd. Address before: Ruiguang road Taiwan Taipei City Neihu district China No. 298 3 floor Patentee before: CENTRAL MEDICAL TECHNOLOGIES Inc. |
|
| TR01 | Transfer of patent right | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: No.12, 19th Floor, No. 93, Section 1, Xintai Fifth Road, Xizhi District, Xinbei City, Taiwan, China, China Patentee after: Thinking biotech Limited by Share Ltd. Address before: 6th floor, 298 Ruiguang Road, Neihu district, Taipei, China Patentee before: Thinking biotech Limited by Share Ltd. |